Drug Profile
BIO 140
Alternative Names: LumencinLatest Information Update: 25 Mar 2008
Price :
$50
*
At a glance
- Originator Molecular Insight Pharmaceuticals
- Class Iodinated contrast media
- Mechanism of Action Emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 02 Nov 2005 No development reported - Preclinical for Cardiovascular disorders (diagnosis) in USA (unspecified route)
- 21 Jan 2003 Preclinical trials in Cardiovascular disorders (diagnosis) in USA (unspecified route)